Tuesday, May 14, 2019 11:18:26 AM
As per the previous Form 7 disclosure the Company continues to undergo its fundamental business change, therefore public trading of its shares remains halted.
The Company had received approval from the listing committee of the CSE for its fundamental change of business. However, with the company signing a letter of intent with Phyto Pharma it is required to amend the listing statement to reflect the new transaction.
The Company has completed the amended listing statement and submitted it to the CSE.
Recent MBAIF News
- Emerging Markets Report: Meeting the Moment • InvestorsHub NewsWire • 11/21/2023 04:18:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM